Back to Journals » Drug Design, Development and Therapy » Volume 14
Review
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®)
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
6,850 | Dovepress* | 6,338+ | 1,061 | 7,399 | |
PubMed Central* | 512 | 386 | 898 | ||
Totals | 6,850 | 1,447 | 8,297 | ||
*Since 17 July 2020 |
View citations on PubMed Central and Google Scholar